Abstract：Objective：To observe the clinical effect of Tripterygium Glycosides combined with Tofacitib on rheumatoid arthritis (RA). Methods：A total of 82 RA patients were divided into the control group and the observation group by random number table method，with 41 patients in each group. The control group was treated with Tofacitib，and the observation group was treated with Tripterygium Glycosides combined with Tofacitib. The relevant parameters of clinical symptoms， and the levels of cytokines， including tumor necrosis factor-α (TNF-α)，interleukin-6 (IL-6)，receptor activator for nuclear factor-κB ligand (RANKL)， C-reactive protein (CRP) and erythrocyte precipitation rate (ESR)，were compared between the two groups before and after treatment，and the clinical effects and adverse reactions in the two groups were evaluated. Results：The total effective rate was 95.12% in the observation group，higher than that of 80.49% in the control group (P＜0.05). After treatment，tender joint counts，swollen joint counts，Visual Analogue Scale (VAS) scores，and the levels of TNF-α，IL-6，RANKL，CRP and ESR in the two groups were decreased when compared with those before treatment (P＜0.05)，and the time of morning stiffness was shortened (P＜0.05). After treatment， tender joint counts， swollen joint counts， VAS scores， and the levels of cytokines in the observation group were lower than those in the control group (P＜0.05)， and the time of morning stiffness was shorter than that in the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion： The therapy of Tripterygium Glycosides combined with Tofacitib has a significant therapeutic effect on RA， which can improve clinical symptoms and inhibit inflammatory responses with great safety.